Windlas Biotech Limited has submitted a regulatory filing to the Listing/Compliance Departments of BSE Limited and the National Stock Exchange of India Limited. The filing is made pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The purpose of the filing is to intimate the schedule of upcoming meetings between company officials and investors/analysts.
Meeting Details
A specific meeting is scheduled for Thursday, July 2, 2026. This will be a group meeting conducted in-person at 12:00 PM.
The participants from the investor/analyst side will be Vara Capital and Apricus Wealth Investment Managers.
The company explicitly states that for these discussions, it will be referring only to all publicly available documents and confirms that no unpublished price sensitive information (UPSI) will be shared during the meeting.
The disclosure includes a note that changes to the schedule may occur due to exigencies on the part of the Investors, Analysts, or the Company itself.
The letter is signed by Ananta Narayan Panda, who holds the designation of Company Secretary & Compliance Officer.